| Assessment Status | Rapid Review Complete |
| HTA ID | 24034 |
| Drug | Erdafitinib |
| Brand | Balversa® |
| Indication | Erdafitinib monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. |
| Assessment Process | |
| Rapid review commissioned | 20/08/2024 |
| Rapid review completed | 17/09/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that erdafitinib not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
